Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2020
Pharma
Gilead's Yescarta shows promise earlier in lymphoma therapy
Gilead Sciences is trumpeting phase 2 data in newly diagnosed lymphoma patients that could bode well for its forthcoming phase 3 results.
Carly Helfand
Dec 8, 2020 8:48am
Takeda pads case for new leukemia use with 5-year survival data
Dec 8, 2020 8:35am
Seagen aims to win over Adcetris holdouts with key 5-year data
Dec 7, 2020 10:00am
J&J shores up Darzalex's lead with another subcutaneous win
Dec 7, 2020 10:00am
AstraZeneca, BeiGene's Imbruvica rivals turn heads with new data
Dec 6, 2020 2:59pm
Novartis makes its Kymriah case in follicular lymphoma
Dec 5, 2020 3:03pm
